GFR-话题@MedSci

#GFR#

483篇内容 | 6252人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534320, encodeId=7c2a15343203f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检, objectType=article, longId=108173, objectId=b73d1081e30c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b73d1081e30c, replyNumber=0, likeNumber=89, createdTime=2017-08-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b73d1081e30c, moduleTitle=EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b73d1081e30c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534319, encodeId=f17f153431998, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR基因突变/ALK基因融合阳性肺鳞癌的靶向治疗, objectType=article, longId=107808, objectId=dadd10e80888, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dadd10e80888, replyNumber=0, likeNumber=124, createdTime=2017-08-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dadd10e80888, moduleTitle=EGFR基因突变/ALK基因融合阳性肺鳞癌的靶向治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dadd10e80888)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534318, encodeId=990c153431890, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Ann Oncol：在全球很大的前瞻性研究中，EGFR突变型患者的临床分子特征和生存数据如何？, objectType=article, longId=107780, objectId=6b6b10e7801a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b6b10e7801a, replyNumber=0, likeNumber=89, createdTime=2017-08-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b6b10e7801a, moduleTitle=Ann Oncol：在全球很大的前瞻性研究中，EGFR突变型患者的临床分子特征和生存数据如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b6b10e7801a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534317, encodeId=fe90153431e7b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=HER-2与抗-EGFR治疗——HER-2与转移性结直肠癌（二）, objectType=article, longId=107697, objectId=953a10e697d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=953a10e697d4, replyNumber=0, likeNumber=95, createdTime=2017-08-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=953a10e697d4, moduleTitle=HER-2与抗-EGFR治疗——HER-2与转移性结直肠癌（二）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=953a10e697d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534316, encodeId=efe315343161e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Eur Radiol：利用MRI特征在预测低级别胶质瘤EGFR表达水平的价值！, objectType=article, longId=107223, objectId=aa3110e223b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa3110e223b6, replyNumber=0, likeNumber=97, createdTime=2017-08-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa3110e223b6, moduleTitle=Eur Radiol：利用MRI特征在预测低级别胶质瘤EGFR表达水平的价值！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa3110e223b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534315, encodeId=26371534315d9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle= LANCET RESPIR MED :埃克替尼对比全脑照射治疗EGFR突变的非小细胞肺癌合并多发脑肿瘤患者（BRAIN）疗效如何？, objectType=article, longId=107158, objectId=cb6710e1581d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb6710e1581d, replyNumber=0, likeNumber=131, createdTime=2017-08-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb6710e1581d, moduleTitle= LANCET RESPIR MED :埃克替尼对比全脑照射治疗EGFR突变的非小细胞肺癌合并多发脑肿瘤患者（BRAIN）疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb6710e1581d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534314, encodeId=346c1534314f2, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ANN ONCOL:血检EGFR突变状态能否指导晚期NSCLC治疗？, objectType=article, longId=106564, objectId=f1911065640d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1911065640d, replyNumber=0, likeNumber=94, createdTime=2017-07-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1911065640d, moduleTitle=ANN ONCOL:血检EGFR突变状态能否指导晚期NSCLC治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1911065640d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534313, encodeId=4c76153431397, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol:呼一口气可鉴别肺癌是否伴有EGFR突变，靠谱吗？, objectType=article, longId=106362, objectId=72d010636264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72d010636264, replyNumber=0, likeNumber=109, createdTime=2017-07-24, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72d010636264, moduleTitle=J Thorac Oncol:呼一口气可鉴别肺癌是否伴有EGFR突变，靠谱吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72d010636264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534312, encodeId=88ab153431214, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JASN：GFR降低对心血管和肾脏的影响孰大孰小？, objectType=article, longId=106143, objectId=47571061433a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47571061433a, replyNumber=0, likeNumber=112, createdTime=2017-07-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47571061433a, moduleTitle=JASN：GFR降低对心血管和肾脏的影响孰大孰小？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47571061433a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534311, encodeId=0b291534311c9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Ann Oncol：血液和肿瘤组织的RAS突变检测方法用于指导mCRC抗EGFR治疗的一致性, objectType=article, longId=105800, objectId=603c10580098, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=603c10580098, replyNumber=0, likeNumber=113, createdTime=2017-07-19, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=603c10580098, moduleTitle=Ann Oncol：血液和肿瘤组织的RAS突变检测方法用于指导mCRC抗EGFR治疗的一致性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=603c10580098)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534310, encodeId=8708153431033, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：多韦替尼治疗BCG无反应FGFR3突变或过表达尿路上皮肿瘤Ⅱ期临床试验结果, objectType=article, longId=104352, objectId=9efe10435266, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9efe10435266, replyNumber=0, likeNumber=0, createdTime=2017-07-04, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9efe10435266, moduleTitle=CLIN CANCER RES：多韦替尼治疗BCG无反应FGFR3突变或过表达尿路上皮肿瘤Ⅱ期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9efe10435266)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534309, encodeId=85e31534309a3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=吉非替尼辅助治疗可以延缓EGFR突变型NSCLC术后复发, objectType=article, longId=103654, objectId=92971036542e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92971036542e, replyNumber=0, likeNumber=84, createdTime=2017-06-29, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92971036542e, moduleTitle=吉非替尼辅助治疗可以延缓EGFR突变型NSCLC术后复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92971036542e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534308, encodeId=dcfc1534308a6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clin Cancer Res：组蛋白脱乙酰酶3克服了EGFR突变型肺癌中奥西替尼耐药性, objectType=article, longId=102803, objectId=048610280344, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=048610280344, replyNumber=0, likeNumber=86, createdTime=2017-06-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=048610280344, moduleTitle=Clin Cancer Res：组蛋白脱乙酰酶3克服了EGFR突变型肺癌中奥西替尼耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=048610280344)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534307, encodeId=257c153430e93, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J CLIN ONCOL:吉非替尼在EGFR拷贝数增益的食管癌患者中疗效显著, objectType=article, longId=102041, objectId=4cf110204168, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cf110204168, replyNumber=0, likeNumber=99, createdTime=2017-06-17, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cf110204168, moduleTitle=J CLIN ONCOL:吉非替尼在EGFR拷贝数增益的食管癌患者中疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cf110204168)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534306, encodeId=db3a1534306c7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理, objectType=article, longId=101597, objectId=6d7510159e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d7510159e72, replyNumber=0, likeNumber=95, createdTime=2017-06-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d7510159e72, moduleTitle=合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d7510159e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534305, encodeId=d0491534305ad, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=ASCO2017 ：VEGFR2 单抗用于复发性胶质母细胞瘤, objectType=article, longId=100862, objectId=d667100862d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d667100862d8, replyNumber=0, likeNumber=105, createdTime=2017-06-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d667100862d8, moduleTitle=ASCO2017 ：VEGFR2 单抗用于复发性胶质母细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d667100862d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534304, encodeId=689c153430431, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thorac Oncol：EGFR检测∣王洁教授全面解析：组织和血检结果的不一致, objectType=article, longId=100606, objectId=857c1006061e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=857c1006061e, replyNumber=0, likeNumber=82, createdTime=2017-06-04, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=857c1006061e, moduleTitle=J Thorac Oncol：EGFR检测∣王洁教授全面解析：组织和血检结果的不一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=857c1006061e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534303, encodeId=fb0515343039c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Ophthalmologica：糖尿病黄斑水肿患者的眼房水中可溶性血管内皮生长因子受体(sVEGFR)和炎症因子的水平显著高于非糖尿病人！, objectType=article, longId=100470, objectId=3fb01004e068, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fb01004e068, replyNumber=0, likeNumber=82, createdTime=2017-06-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fb01004e068, moduleTitle=Ophthalmologica：糖尿病黄斑水肿患者的眼房水中可溶性血管内皮生长因子受体(sVEGFR)和炎症因子的水平显著高于非糖尿病人！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fb01004e068)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534302, encodeId=e1491534302da, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=MOL CANCER THER：非小细胞肺癌细胞对EGFR -酪氨酸激酶抑制剂埃罗替尼的敏感性, objectType=article, longId=100144, objectId=644a100144e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644a100144e7, replyNumber=0, likeNumber=36, createdTime=2017-05-31, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644a100144e7, moduleTitle=MOL CANCER THER：非小细胞肺癌细胞对EGFR -酪氨酸激酶抑制剂埃罗替尼的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=644a100144e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534301, encodeId=cfd315343010b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CANCER RES：转移性结直肠癌患者抗EGFR单克隆抗体获得性耐药的异质性, objectType=article, longId=99880, objectId=4d2e9988075, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d2e9988075, replyNumber=0, likeNumber=90, createdTime=2017-05-28, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d2e9988075, moduleTitle=CLIN CANCER RES：转移性结直肠癌患者抗EGFR单克隆抗体获得性耐药的异质性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d2e9988075)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检

2017-08-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR基因突变/ALK基因融合阳性肺鳞癌的靶向治疗

2017-08-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Ann Oncol：在全球很大的前瞻性研究中，EGFR突变型患者的临床分子特征和生存数据如何？

2017-08-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

HER-2与抗-EGFR治疗——HER-2与转移性结直肠癌（二）

2017-08-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Eur Radiol：利用MRI特征在预测低级别胶质瘤EGFR表达水平的价值！

2017-08-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

LANCET RESPIR MED :埃克替尼对比全脑照射治疗EGFR突变的非小细胞肺癌合并多发脑肿瘤患者（BRAIN）疗效如何？

2017-08-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ANN ONCOL:血检EGFR突变状态能否指导晚期NSCLC治疗？

2017-07-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol:呼一口气可鉴别肺癌是否伴有EGFR突变，靠谱吗？

2017-07-24

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JASN：GFR降低对心血管和肾脏的影响孰大孰小？

2017-07-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Ann Oncol：血液和肿瘤组织的RAS突变检测方法用于指导mCRC抗EGFR治疗的一致性

2017-07-19

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：多韦替尼治疗BCG无反应FGFR3突变或过表达尿路上皮肿瘤Ⅱ期临床试验结果

2017-07-04

liuyiping (审核中...)

前往app查看评论内容

#GFR#

吉非替尼辅助治疗可以延缓EGFR突变型NSCLC术后复发

2017-06-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Clin Cancer Res：组蛋白脱乙酰酶3克服了EGFR突变型肺癌中奥西替尼耐药性

2017-06-23

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J CLIN ONCOL:吉非替尼在EGFR拷贝数增益的食管癌患者中疗效显著

2017-06-17

liuyiping (审核中...)

前往app查看评论内容

#GFR#

合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理

2017-06-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

ASCO2017 ：VEGFR2 单抗用于复发性胶质母细胞瘤

2017-06-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thorac Oncol：EGFR检测∣王洁教授全面解析：组织和血检结果的不一致

2017-06-04

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Ophthalmologica：糖尿病黄斑水肿患者的眼房水中可溶性血管内皮生长因子受体(sVEGFR)和炎症因子的水平显著高于非糖尿病人！

2017-06-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

MOL CANCER THER：非小细胞肺癌细胞对EGFR -酪氨酸激酶抑制剂埃罗替尼的敏感性

2017-05-31

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CANCER RES：转移性结直肠癌患者抗EGFR单克隆抗体获得性耐药的异质性

2017-05-28

科室
- - 订阅+
  - 更多科室
工具
服务